CClinicalTrials.gg
CompletedNCT03066414ReVAsUpdated Feb 28, 2017

Respiratory Variations For Assessing Blood Withdrawal

An observational study in Genetic Hemochromatosis, sponsored by University Hospital, Lille. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-02-28.

Sponsored by University Hospital, Lille · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
27
Ages
18 Years and older
Sex
All
01

Study summary

OBJECTIVES: To investigate whether respiratory variations of the inferior vena cava (ΔIVC) and internal jugular vein (ΔIJV) diameters during standardized breathing (ΔIVCST and ΔIJVST) increase after a therapeutic bleeding in spontaneously breathing and non-obese patients with genetic hemochromatosis.

DESIGN: Prospective, monocentric study in the EFS Nord-de-France blood center.

PATIENTS: Non-obese patients with genetic hemochromatosis undergoing a therapeutic bleeding.

INTERVENTIONS: Ultrasound measures and collected clinical parameters before and after a therapeutic bleeding, during a standardized respiratory maneuver.

MAIN OUTCOME AND MEASURES: The primary endpoint was the ΔIVCST change induced by a 300 to 500ml therapeutic bleeding. It measured the minimal and maximal IVC and IJV diameters during a standardized respiratory maneuver. ΔIVCST and ΔIJVST were calculated as follows: [(maximal diameter - minimal diameter)/maximal diameter].100.

02

Conditions studied

  • Genetic Hemochromatosis

Keywords

  • hemochromatosis
  • blood withdrawal
  • respiratory variations
  • inferior vena cava
  • internal jugular vein
  • ultrasound
  • ultrasonography
  • echography
03

In context

Hemochromatosis

67 studies on the registry are indexed under Hemochromatosis; 4 are open to participants now.

This study's enrollment of 27 is below the median of 100 across 18 observational studies indexed under Hemochromatosis.

Browse Hemochromatosis studies →

Lead sponsor

University Hospital, Lille is the lead sponsor of 625 studies on the registry; 141 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Non-obese patients with genetic hemochromatosis

Inclusion criteria

  • adult patients of > or equal 18 years
  • genetic hemochromatosis
  • undergoing a therapeutic blood withdrawal
  • health insured
  • non-obese (body mass index \<30Kg/m²)

Exclusion criteria

Exclusion Criteria:

  • pregnancy
  • transthoracic echogenicity unsuitable for measuring the inferior vena cava diameters
  • clinical signs of active exhalation
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
27 participants (actual)
Patient registry
No

Groups and cohorts

  • non-obese patients with genetic hemochromatosis

    PATIENTS: Non-obese patients with genetic hemochromatosis undergoing a therapeutic bleeding. INTERVENTIONS: The investigators performed ultrasound measurements (echography) and collected clinical parameters before and after a 300 to 500ml therapeutic bleeding, during a standardized respiratory maneuver.

    Procedure: echography

Interventions

  • Procedureechography

    The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver

06

What researchers measure

Primary outcomes

  1. blood withdrawal-induced changes in the respiratory variations of the inferior vena cava during a standardized respiratory maneuver (ΔIVCST)

    The primary endpoint was the ΔIVCST change induced by a 300 to 500ml therapeutic bleeding. The investigators measured the minimal and maximal IVC diameters during a standardized ventilation. ΔIVCST was calculated as follows: \[(maximal diameter - minimal diameter)/maximal diameter\].100.

    Time frame: during a standardized respiratory maneuver, an average 1 hour maximum

Secondary outcomes

  1. blood withdrawal-induced changes in the respiratory variations of the internal jugular vein during a standardized respiratory maneuver (ΔIJVST)

    The primary endpoint was the ΔIJVST change induced by a 300 to 500ml therapeutic bleeding. The investigators measured the minimal and maximal IJV diameters during a standardized ventilation. ΔIJVST was calculated as follows: \[(maximal diameter - minimal diameter)/maximal diameter\].100.

    Time frame: during a standardized respiratory maneuver, an average 1 hour maximum

07

Study locations

1 site
  • Hôpital Roger Salengro, CHRU de Lille
    Lille, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 28, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03066414
Lead sponsor
University Hospital, Lille
Responsible party
Sponsor
First posted
Feb 28, 2017
Start date
Feb 2015
Primary completion
Jun 2016
Completion
Jun 2016
Last update
Feb 28, 2017

Study contacts

Sébastien Preau, MD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion